News

This episode of Tuning Into The C-Suite welcomes our first of many episodes part of the new “Meet the Board” podcast series. Listeners will now hear from a member of Managed Healthcare Executive's Editorial Advisory Board once a month at the end of each month. The first guest featured is Physician and former Executive VP of the American Cancer Society, Otis Brawley. Brawley is a Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University.

Independence Blue Cross and Signify Health have put together of community organizations and other services to address the social determinants of health and provide in-home care.

The work of moving away from fee for service is in progress. The results so far? Mixed.

Pfizer snagged its fourth indication for the blockbuster medication tofacitinib (Xeljanz) for children and adolescents 2 years and older with active polyarticular course juvenile idiopathic arthritis (pcJIA).

Xanax and Ativan are among the medications impacted by FDA’s new requirements.

Penn’s Amol Navathe, M.D., Ph.D., and colleagues reported favorable results in Health Affairs. Navathe is featured in this second of a two part video series.

Researchers compare beneficiaries with end-stage renal disease in a Medicare Advantage Special Needs Plan sponsored by CareMore to patients in traditional Medicare, explains Amol Navathe, M.D., Ph.D., an assistant professor in the Department of Medical Ethics and Health Policy at University of Pennsylvania’s Perelman School of Medicine, in this first of two part video series.

Can data mined from EHRs match that from the gold standard, randomized clinical trials?

Sun Pharmaceuticals issued a voluntary recall of 1 lot of its metformin hydrochloride for extended-release (ER) oral suspension (Riomet ER), 500 mg per 5 mL.

Drug cost-effectiveness group announces that it is branching out into evaluating payer formularies and drug cost-sharing policies.

Negative results for semorinemab have deflated some of the hopes for a tau as a target, although a winning strategy Alzheimer's may involve hitting several targets at once, including tau.

The Alliance of Community Health Plans calls for changes to get more biosimilars approved and on the market.

Texas Oncology Executive Vice President Debra Patt says it will be unrealistically expensive for oncologists to keep many biosimilars for the same innovator product in their inventories.

Those who have avoided visiting or put off their annual physical appointments at the doctor's office due to fears of contracting COVID-19 do not have put off those appointments any longer.

The coronavirus pandemic has shed light on major imbalances within the healthcare system, specifically, the supply and demand of allied health professionals, and the urgent need to invest in community-based care that prioritizes vulnerable populations.

After three months of recovery, financial and volume indicators were off in August, according to Kaufman Hall's monthly report.

CMS is putting more weight on patient experience measures in its Medicare Advantage and Part D Star ratings. What health plans can do now to improve their ratings.

COVID-19 is certainly important. But oncologists, people with cancer, and complex ecosystem of cancer care in the U.S. are grappling with other important issues such as reimbursement, distorted incentives, the implications of the massive amount of data that is available, and, of course, high costs and prices. Included are thoughts from five experts on these challenges and how they might be met.

CMS says 26.9 million beneficiaries are expected to enroll in Medicare Advantage plans in 2021.

CMS is taking prior authorization for frequent, non-emergency ambulance transportation nationwide and launching a model that pay ambulance services for taking patients to nonhospital facilities.

Health systems are struggling as a result of the reduced activity of elective procedures, the loss of health coverage for many employees, and the resultant drop in billings. According to this article, there are seven approaches recommended for immediate consideration to increase revenues and stanch losses.

The Trump administration’s attempts at pulling back the curtain have ended up in court.

In this week's episode of Tuning Into The C-Suite, MHE's Briana Contreras spoke with Dr. Peter Alperin, Vice President of Doximity and a physician in private practice in San Francisco. They discussed the recently released 2020 State of Telemedicine Report conducted by Doximity and how it reflects into the adoption of telemedicine among physicians and patients alike, how the report analyzed telemedicine’s usage since COVID-19 and its market potential beyond the pandemic.

The COVID-19 pandemic has tested every healthcare executive’s ability to adjust — and adjust again. From mid-March through summer and now early fall, the ups and downs of the outbreak have occurred at a furious, unpredictable cadence.

The White House and other partners released the speedy COVID-19 vaccine distribution strategy called Operation Warp Speed.

Some of the top medications were approved this summer, while others are awaiting FDA approval.

Both recalls are due to sub-potency of drugs that treat hypothyroidism.

CVS Health, Walgreens and Walmart are pushing ahead with ambitious plans for in-store clinics and doctor’s offices.